Genmab (NASDAQ:GMAB) 주식

Genmab

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Coinbase Photo by Useacoin on Shutterstock

Equities

Large Cap

News

Movers

Trading Ideas

AAPL

ADBE

COIN

EXPE

GMAB

HOOD

IBKR

SAIL

이들 대형 주식은 지난주에 최악의 성과를 보였다. 이 주식이 당신의 포트폴리오에 있나요? 1. 테라다인(NASDAQ:TER)의 주가가 20.08% 하락했다. 이 회사는 포토닉 IC 테스트 회사인 퀀티파이 포토닉스(Quantifi Photonics)를 비공개 금액에 인수하기로 합의했다. 애널리스트들은 이 회사의 가격 전망을 하향 조정했다.

코인베이스, 애플, 로빈후드 등 지난주 급락한 대형주 12종목 (3월 10일-3월 14일)

Genmab AS

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Barclays analyst Lauren Lieberman downgraded the rating for PepsiCo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>) from Overweight to Equal-Weight and lowered the price target from $168 to $156. PepsiCo shares closed at $151.34 on Monday. <a href="https://www.benzinga.com/quote/pep/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Guggenheim analyst Michael Schmidt downgraded Incyte Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) from Buy to Neutral and maintained the price target of $92. Incyte shares closed at $62.01 on Monday. <a href="https://www.benzinga.com/quote/INCY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst Julien Dumoulin-Smith downgraded TPI Composites, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPIC#NASDAQ">TPIC</a>) from Hold to Underperform and lowered the price target from $2.3 to $0.5. TPI Composites shares closed at $1.20 on Monday. <a href="https://www.benzinga.com/quote/TPIC/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>UBS analyst Steven Fisher downgraded PACCAR Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCAR#NASDAQ">PCAR</a>) from Buy to Neutral and announced a $108 price target. PACCAR shares closed at $101.17 on Monday. <a href="https://www.benzinga.com/quote/PCAR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>William Blair analyst Y Katherine Xu downgraded the rating for Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) from Outperform to Market Perform. Incyte shares closed at $62.01 on Monday.  <a href="https://www.benzinga.com/quote/ONCY/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying PEP stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="571" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/18120202/image-151-1024x571.png" alt="" class="wp-image-829930" style="width:592px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/18120202/image-151-1024x571.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/18120202/image-151-300x167.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/18120202/image-151-768x428.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/18120202/image-151.png 1135w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/03/44355158/jim-cramer-says-this-tech-stock-is-a-meme-stock-recommends-buying-accenture">Jim Cramer Calls This Stock A &#8216;Meme Stock,&#8217; Recommends Buying Accenture</a></li>
</ul>

Downgrades

Markets

Analyst Ratings

INCY

PCAR

TPIC

This PepsiCo Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

Morgan Stanley analyst Ronald Kamdem maintains Paramount Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PGRE#NYSE">PGRE</a>) with a Equal-Weight and lowers the price target from $4.25 to $4.

Price Target

PGRE

Morgan Stanley Maintains Equal-Weight on Paramount Group, Lowers Price Target to $4

Jaguar Health Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) shares are trading lower by 40.1% to 28 cents during Tuesday&#8217;s session after the company announced a <a href="https://www.benzinga.com/pressreleases/25/03/ac44375204/jaguar-health-inc-announces-reverse-stock-split">1-for-25 reverse stock split</a> of its common stock, set to take effect on March 24, to maintain compliance with Nasdaq listing requirements.
The stock will trade on a split-adjusted basis under the same ticker. CEO Lisa Conte stated the move aims to attract institutional investors by adjusting the share price and count. 
Approved by stockholders at a Special Meeting, the split will convert every 25 shares into one without changing par value. 
No fractional shares will be issued, and stockholders will receive cash for fractions. Equiniti Trust Company, LLC will manage the exchange, with brokerage account holders requiring no action.
Read Also: <a href="https://www.benzinga.com/trading-ideas/technicals/25/03/44378861/stock-of-the-day-does-classic-pattern-in-microsoft-mean-a-move-higher">Stock Of The Day – Does Classic Pattern In Microsoft Mean A Move Higher?</a>
<h2 class="wp-block-heading">Is JAGX A Good Stock To Buy?</h2>
An investor can make a few decisions when deciding whether a stock is a good buy. In addition to valuation metrics and price action which you can find on Benzinga's quote pages &#8211; like <a href="https://www.benzinga.com/quote/JAGX">Jaguar Health</a>&#8216;s page for example &#8211; there are factors like whether or not a company pays a dividend or buys a large portion of its stock each quarter.
Buyback programs are obviously different and highly variable. A company can approve a buyback program and purchase shares as it sees fit over the course of time in which the buyback was authorized. Looking through the latest news on <a href="https://www.benzinga.com/quote/JAGX">Jaguar Health</a> will often yield whether or not the company has approved a buyback program recently. Buyback programs usually serve as a support for share prices, serving as a backstop for demand.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, JAGX has a 52-week high of $21.60 and a 52-week low of $0.32.

JAGX

Why Jaguar Health (JAGX) Stock Is Trading Lower

RTX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>) has outperformed the market over the past 5 years by 2.68% on an annualized basis producing an average annual return of 22.92%. Currently, RTX has a market capitalization of $176.06 billion. 
Buying $1000 In RTX: If an investor had bought $1000 of RTX stock 5 years ago, it would be worth $2,548.67 today based on a price of $131.87 for RTX at the time of writing.
<h3>RTX's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742313654_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning RTX Stock In The Last 5 Years

Investors with a lot of money to spend have taken a bearish stance on Arista Networks (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANET#NYSE">ANET</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ANET, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 17 uncommon options trades for Arista Networks.
This isn't normal.
The overall sentiment of these big-money traders is split between 35% bullish and 47%, bearish.
Out of all of the special options we uncovered, 9 are puts, for a total amount of $972,160, and 8 are calls, for a total amount of $656,220.
<h3>Predicted Price Range</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $70.0 and $122.5 for Arista Networks, spanning the last three months.
<h3>Volume &amp; Open Interest Trends</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Arista Networks's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Arista Networks's substantial trades, within a strike price spectrum from $70.0 to $122.5 over the preceding 30 days.
<h3>Arista Networks 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742313645_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ANET</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$16.8</td>
<td>$16.6</td>
<td>$16.64</td>
<td>$90.00</td>
<td>$415.2K</td>
<td>733</td>
<td>254</td>
</tr>
<tr>
<td>ANET</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$18.1</td>
<td>$18.0</td>
<td>$18.0</td>
<td>$100.00</td>
<td>$235.8K</td>
<td>1.1K</td>
<td>150</td>
</tr>
<tr>
<td>ANET</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$11.0</td>
<td>$10.5</td>
<td>$10.5</td>
<td>$75.00</td>
<td>$210.0K</td>
<td>487</td>
<td>200</td>
</tr>
<tr>
<td>ANET</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$0.8</td>
<td>$0.7</td>
<td>$0.7</td>
<td>$122.50</td>
<td>$140.0K</td>
<td>5.0K</td>
<td>1.9K</td>
</tr>
<tr>
<td>ANET</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$18.2</td>
<td>$17.9</td>
<td>$18.03</td>
<td>$80.00</td>
<td>$90.1K</td>
<td>1.4K</td>
<td>52</td>
</tr>
</tbody>
</table>

<h3>About Arista Networks</h3>
Arista Networks is a networking equipment provider that primarily sells Ethernet switches and software to data centers. Its marquee product is its extensible operating system, or EOS, that runs a single image across every single one of its devices. The firm operates as one reportable segment. It has steadily gained market share since its founding in 2004, with a focus on high-speed applications. Arista counts Microsoft and Meta Platforms as its largest customers and derives roughly three quarters of its sales from North America.
Having examined the options trading patterns of Arista Networks, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Current Position of Arista Networks</h3>
<ul>
<li>Currently trading with a volume of 3,380,910, the ANET's price is down by -1.36%, now at $83.93. </li>
<li>RSI readings suggest the stock is currently may be approaching oversold.</li>
<li>Anticipated earnings release is in 49 days.</li>
</ul>
<h3>Expert Opinions on Arista Networks</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $119.8.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from UBS continues to hold a Neutral rating for Arista Networks, targeting a price of $112. 
&#x2A; Consistent in their evaluation, an analyst from Wells Fargo keeps a Overweight rating on Arista Networks with a target price of $125. 
&#x2A; An analyst from Barclays persists with their Overweight rating on Arista Networks, maintaining a target price of $126. 
&#x2A; An analyst from Citigroup has decided to maintain their Buy rating on Arista Networks, which currently sits at a price target of $121. 
&#x2A; In a positive move, an analyst from UBS has upgraded their rating to Buy and adjusted the price target to $115. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Arista Networks options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Options

ANET

Arista Networks's Options Frenzy: What You Need to Know

Financial giants have made a conspicuous bearish move on Taiwan Semiconductor. Our analysis of options history for Taiwan Semiconductor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) revealed 65 unusual trades.
Delving into the details, we found 27% of traders were bullish, while 61% showed bearish tendencies. Out of all the trades we spotted, 30 were puts, with a value of $3,476,335, and 35 were calls, valued at $4,896,222.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $110.0 to $220.0 for Taiwan Semiconductor over the recent three months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Taiwan Semiconductor's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Taiwan Semiconductor's whale trades within a strike price range from $110.0 to $220.0 in the last 30 days. 
<h3>Taiwan Semiconductor 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742313640_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TSM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$13.2</td>
<td>$13.05</td>
<td>$13.05</td>
<td>$170.00</td>
<td>$2.6M</td>
<td>6.8K</td>
<td>2.0K</td>
</tr>
<tr>
<td>TSM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$10.0</td>
<td>$9.95</td>
<td>$9.95</td>
<td>$165.00</td>
<td>$888.5K</td>
<td>6.3K</td>
<td>953</td>
</tr>
<tr>
<td>TSM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$9.45</td>
<td>$9.3</td>
<td>$9.45</td>
<td>$140.00</td>
<td>$567.0K</td>
<td>4.6K</td>
<td>1.0K</td>
</tr>
<tr>
<td>TSM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$8.95</td>
<td>$8.8</td>
<td>$8.9</td>
<td>$150.00</td>
<td>$150.4K</td>
<td>9.2K</td>
<td>569</td>
</tr>
<tr>
<td>TSM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$6.6</td>
<td>$6.45</td>
<td>$6.55</td>
<td>$155.00</td>
<td>$142.1K</td>
<td>3.5K</td>
<td>720</td>
</tr>
</tbody>
</table>

<h3>About Taiwan Semiconductor</h3>
Taiwan Semiconductor Manufacturing Co. is the world's largest dedicated chip foundry, with over 60% market share. TSMC was founded in 1987 as a joint venture of Philips, the government of Taiwan, and private investors. It went public as an ADR in the US in 1997. TSMC's scale and high-quality technology allow the firm to generate solid operating margins, even in the highly competitive foundry business. Furthermore, the shift to the fabless business model has created tailwinds for TSMC. The foundry leader has an illustrious customer base, including Apple, AMD, and Nvidia, that looks to apply cutting-edge process technologies to its semiconductor designs. TSMC employs more than 73,000 people.
<h3>Taiwan Semiconductor's Current Market Status</h3>
<ul>
<li>Trading volume stands at 4,802,447, with TSM's price down by -1.87%, positioned at $172.27.</li>
<li>RSI indicators show the stock to be may be approaching oversold.</li>
<li>Earnings announcement expected in 30 days.</li>
</ul>
<h3>Professional Analyst Ratings for Taiwan Semiconductor</h3>
Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $225.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; In a cautious move, an analyst from Needham downgraded its rating to Buy, setting a price target of $225. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Taiwan Semiconductor, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Check Out What Whales Are Doing With TSM

Investors with a lot of money to spend have taken a bearish stance on Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ABT, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 10 uncommon options trades for Abbott Laboratories.
This isn't normal.
The overall sentiment of these big-money traders is split between 30% bullish and 60%, bearish.
Out of all of the special options we uncovered, 2 are puts, for a total amount of $305,520, and 8 are calls, for a total amount of $280,024.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $75.0 to $135.0 for Abbott Laboratories over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Abbott Laboratories's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Abbott Laboratories's substantial trades, within a strike price spectrum from $75.0 to $135.0 over the preceding 30 days.
<h3>Abbott Laboratories Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742313635_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$13.9</td>
<td>$13.4</td>
<td>$13.4</td>
<td>$130.00</td>
<td>$245.2K</td>
<td align="right">8</td>
<td align="right">228</td>
</tr>
<tr>
<td>ABT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$14.25</td>
<td>$13.4</td>
<td>$13.4</td>
<td>$130.00</td>
<td>$60.3K</td>
<td align="right">8</td>
<td align="right">45</td>
</tr>
<tr>
<td>ABT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$5.75</td>
<td>$5.65</td>
<td>$5.65</td>
<td>$135.00</td>
<td>$47.4K</td>
<td align="right">456</td>
<td align="right">325</td>
</tr>
<tr>
<td>ABT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$4.9</td>
<td>$4.85</td>
<td>$4.9</td>
<td>$135.00</td>
<td>$39.2K</td>
<td align="right">507</td>
<td align="right">174</td>
</tr>
<tr>
<td>ABT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$4.85</td>
<td>$4.8</td>
<td>$4.8</td>
<td>$135.00</td>
<td>$36.9K</td>
<td align="right">507</td>
<td align="right">352</td>
</tr>
</tbody>
</table>

<h3>About Abbott Laboratories</h3>
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Having examined the options trading patterns of Abbott Laboratories, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Current Position of Abbott Laboratories</h3>
<ul>
<li>Trading volume stands at 2,698,821, with ABT's price down by -1.06%, positioned at $126.28.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 29 days.</li>
</ul>
<h3>Professional Analyst Ratings for Abbott Laboratories</h3>
3 market experts have recently issued ratings for this stock, with a consensus target price of $154.67.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Goldman Sachs has decided to maintain their Buy rating on Abbott Laboratories, which currently sits at a price target of $154. 
&#x2A; An analyst from Citigroup persists with their Buy rating on Abbott Laboratories, maintaining a target price of $160. 
&#x2A; An analyst from B of A Securities has decided to maintain their Buy rating on Abbott Laboratories, which currently sits at a price target of $150. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Abbott Laboratories with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

Decoding Abbott Laboratories's Options Activity: What's the Big Picture?

Morgan Stanley analyst Simeon Gutman maintains Okta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKTA#NASDAQ">OKTA</a>) with a Overweight and raises the price target from $106 to $125.

OKTA

Morgan Stanley Maintains Overweight on Okta, Raises Price Target to $125

WIIM

TSLA

Tesla shares are trading lower after RBC Capital cut its price target on the stock from $440 to $320. Additionally, the stock may be moving down after competitor Zeekr announced its rolling out advanced driver-assistance capabilities.

Scienture Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCNX#NASDAQ">SCNX</a>) shares initially traded higher on Tuesday but have since reversed after the Food and Drug Administration (FDA) approved its <a href="https://www.benzinga.com//node/44374406">new drug application for Arbli.</a>
What To Know: Arbli (losartan potassium) is first and only FDA approved ready-to-use oral liquid losartan available in the United States.
It is designed to treat hypertension in patients over 6 years old, reduce stroke risk in patients with hypertension and left ventricular hypertrophy and treat diabetic nephropathy in certain patients with type 2 diabetes.
&#8220;We are pleased to bring to market, Arbli, a transformative therapy option containing losartan, one of the most widely prescribed molecules in its class, to patients, caregivers and healthcare professionals. We expect to commercially launch and make Arbli&nbsp;available to patients in the U.S. in&nbsp;Q3&nbsp;2025,&#8221; said Narasimhan Mani, President of Scienture.
See Also: <a href="https://www.benzinga.com/25/03/44378672/defense-stocks-are-soaring-expert-sees-170-as-achievable-by-year-end-for-this-preferred-pick">EXCLUSIVE: This Defense Stock Could Hit $170 &#8216;Before Year-End,&#8217; Expert Explains Why</a>
SCNX Price Action: At the time of writing, Scienture stock is trading 16.5% lower at $2.07, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: via Shutterstock

SCNX

What's Going On With Scienture Shares Tuesday?

Tilray Brands, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) saw its shares rise on Tuesday following the<a target="_blank" href="https://www.benzinga.com/news/earnings/25/03/44329381/this-week-in-cannabis-earnings-europes-buzzing-scene-the-un-and-more" rel="noreferrer noopener"> announcement of a product expansion</a>.
Manitoba Harvest, a leading hemp food company under Tilray, has launched its new Superseed Snack Clusters, which are available at <a href="https://www.benzinga.com//node/44372978">select Whole Foods Market stores nationwide.</a>
These snacks are crafted with a blend of premium seeds, including hemp hearts, pumpkin seeds, sunflower seeds, chia, and flax, offering a delicious and nutritious option for health-conscious consumers.
Each serving of Manitoba Harvest&#8217;s Superseed Snack Clusters provides 5 grams of plant-based protein, essential fatty acids, fiber, and a range of essential vitamins and minerals.
Available in three flavors – Maple Cinnamon, Dark Chocolate, and Smoky BBQ – these clusters aim to meet the growing demand for functional, guilt-free snacks.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/25/03/44378155/exclusive-trumps-200-tariff-threat-could-price-european-alcohol-out-of-us-markets" rel="noreferrer noopener">EXCLUSIVE: Trump&#8217;s 200% Tariff Threat Could Price European Alcohol Out Of US Markets</a>
In addition to the snack launch, Tilray recently revealed an expansion for its <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/03/44283925/whats-going-on-with-cannabis-firm-tilray-brands-stock-on-wednesday" rel="noreferrer noopener">non-alcoholic craft beer brand, Runner&#8217;s High Brewing</a>.
The brand will now be available at 4,500 new distribution points, including major retailers like Publix, HEB, Harris Teeter, and Lowes Foods.
The move aims to make Runner&#8217;s High a go-to beverage for health-conscious consumers and beer lovers, offering varieties like Golden Wheat, Raspberry Wheat, and Dark Chocolate.
Tilray&#8217;s strategic moves to diversify its product portfolio reflect its commitment to wellness-focused offerings that cater to a growing market of health-minded individuals.
Price Action: TLRY shares are trading higher by 4.26% to $0.6720 at last check Tuesday.
Read also:
<ul>
<li><a href="https://www.benzinga.com/25/03/44376760/the-mag-7-slowdown-a-more-durable-transition-or-just-another-blip" target="_blank" rel="noreferrer noopener">EXCLUSIVE: The Mag 7 Slowdown – A &#8216;More Durable Transition&#8217; Or Just Another Blip?</a></li>
</ul>
Image Source: Tilray Brands, Inc.

General

TLRY

Tilray's Manitoba Harvest Rolls Out Superseed Snacks At Whole Foods

A Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) analyst is significantly lowering the price target on the stock with concerns on full self-driving pricing and vehicle demand.
The analyst note comes with continued reports of low sales and used vehicle prices.
The Tesla Analyst: RBC Capital analyst Tom Narayan maintained an Outperform rating on Tesla while lowering the price target from $440 to $320.
"Much of the attention around Tesla has centered on its recent delivery performance in Jan and Feb in Europe and China," Narayan said.
Demand fears are likely overblown, according to Narayan. Europe and China, where Tesla is losing market share, represent a small portion of Tesla's overall vehicle sales, he adds.
Along with the potential for demand concerns, the analyst lowers FSD pricing assumptions and robotaxi penetration rates.
Narayan said FSD pricing could drop from $100/month today to $50/month in 2026.
"Level 2+ autonomy offerings are increasingly becoming standard features with some OEMs intentionally not seeking to make it a profit center, but rather as a product differentiator."
Tesla could also see lower than previously anticipated market share for robotaxis in Europe and China. It&#8217;s likely that domestic OEMs "dominate the market,&#8221; he says.
The latest price and market share changes lead to a lower sum-of-the-parts valuation with FSD going from $383 billion to $211 billion and robotaxis going from $879 billion to $641 billion.
Narayan also forecasts lower deliveries with an estimate of 11% delivery growth in fiscal 2025, down from an original forecast of 14% delivery growth.
Why It's Important: The big question from Narayan and other analysts is whether the lower delivery numbers are due to "political dynamics,&#8221; or have to do with the planned factory shutdowns for the Model Y refresh. Perhaps it&#8217;s a combination of both.
Electrek recently highlighted the sharp decline in used car prices for Tesla vehicles. The report said Tesla used car prices are falling three times the rate of the overall used car market.
Using data from CarGurus, the report said Tesla used prices are down 3.7% over the last three months and down 7.3% over the last year, compared to drops of 1.1% and 2.7% respectively for the overall used car market.
Among Tesla vehicles, the used car prices for the Cybertruck and Model S have been hit hardest falling 11.5% and 8.3% respectively over the last three months.
Benzinga recently polled readers to see if President Donald Trump&#8216;s purchase and praise for Tesla would impact their future vehicle-buying activity.
&#8220;Donald Trump recently bought a Tesla. How does this affect your view of Tesla?&#8221; Benzinga asked.
Here are the results:
<ul>
<li>I will never own a Tesla: 53%</li>
<li>I&#8217;m more likely to buy a Tesla:&nbsp;23%</li>
<li>I&#8217;m less likely to buy a Tesla: 14%</li>
<li>I already own a Tesla: 10%</li>
</ul>
The poll may have some bad news for Tesla fans and investors with the majority saying they will never own a Tesla vehicle.
The good news is that of undecided non-Tesla owners, 23% said they are more likely to buy a Tesla while 14% said they are less likely to buy a Tesla on account of Trump&#8217;s purchase and sales pitch for the EV company.
Tesla&#8217;s sales have dropped sharply in recent weeks, accompanied by demonstrations and vandalization against the company&#8217;s&nbsp;<a href="https://www.benzinga.com/25/03/44135841/elon-musk-slams-attacks-on-tesla-vehicles-after-incident-in-brookline-vandalism-is-not-free-speech" target="_blank" rel="noreferrer noopener">vehicles</a>, dealerships and charging hubs, according to&nbsp;<a href="https://abcnews.go.com/US/tesla-vehicles-destroyed-vandalized-musk-began-role-white/story?id=119677836" target="_blank" rel="noreferrer noopener">ABC News</a>. Declining sales are evident not just in the U.S., but also&nbsp;<a href="https://www.benzinga.com/news/25/03/44209579/unprecedented-slide-tesla-sales-plummet-45-in-europe-as-musks-net-worth-dives-5-2b-in-a-week" target="_blank" rel="noreferrer noopener">throughout Europe</a>,&nbsp;<a href="https://www.benzinga.com/tech/25/03/44069703/tesla-china-wholesale-numbers-are-unimportant-says-researcher-heres-what-matters-more" target="_blank" rel="noreferrer noopener">China</a>, and Australia.
A recent report from Electrek citing inventory checks and new order delivery timelines in the U.S. shows that so far Trump&#8217;s purchase and event has had&nbsp;<a href="https://www.benzinga.com/markets/25/03/44346155/trumps-tesla-shoutout-falls-flat-no-spike-in-orders-or-inventory-movement" target="_blank" rel="noreferrer noopener">a minimal impact&nbsp;</a>on Tesla&#8217;s sales and demand.
Tesla&#8217;s first-quarter sales figures, which will include the month of March will be among the most watched in recent years given boycotts, sales declines in Europe and now Trump&#8217;s sales pitch.
TSLA Price Action:&nbsp;Tesla stock is down 6% to $223.76 on Tuesday versus a 52-week trading range of $138.80 to $488.54. Tesla stock is down 41.0% year-to-date in 2025 and up 28.8% over the last year.
Tesla stock is now trading below where it was when Trump won the 2024 election. Tesla stock closed at $251.44 on Nov. 5 and opened for trading at $284.67 on Nov. 6 after&nbsp;<a href="https://www.benzinga.com/news/24/11/41768178/donald-trump-defeats-kamala-harris-to-win-2024-election" target="_blank" rel="noreferrer noopener">Trump&#8217;s victory was confirmed</a>.
The stock is down over 50% from all-time highs set in December.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/news/25/03/44339973/trump-said-nobody-wants-to-buy-evs-2-years-ago-now-hes-endorsing-and-says-hes-buying-a-tesla-heres-what-else-hes-been-saying-about-evs">Trump Said &#8216;Nobody Wants To Buy&#8217; EVs 2 Years Ago—Now He&#8217;s Endorsing Tesla At The White House</a></li>
</ul>
Image: Shutterstock

Analyst Color

Reiteration

Tesla Analyst Says Demand Fears 'Overblown,' But Has Some Concerns As Used Car Prices Plummet

Morgan Stanley analyst Hamza Fodderwala maintains Jamf Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAMF#NASDAQ">JAMF</a>) with a Equal-Weight and lowers the price target from $20 to $16.

JAMF

Morgan Stanley Maintains Equal-Weight on Jamf Holding, Lowers Price Target to $16

Shares of major Europe-related ETFs are trading higher after the German parliament passed debt reforms which is expected to lead to an increase in defence and infrastructure spending.

Morgan Stanley analyst Ronald Kamdem maintains Hudson Pacific Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPP#NYSE">HPP</a>) with a Underweight and lowers the price target from $2.4 to $2.25.

Morgan Stanley Maintains Underweight on Hudson Pacific Properties, Lowers Price Target to $2.25

Bitcoin's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) bull cycle appears to have <a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44377385/bitcoin-remains-stuck-in-the-low-80000s-what-does-technical-analysis-say">come to an end</a>, according to Ki Young Ju, Founder and CEO of blockchain analytics firm CryptoQuant.
The comments follow fresh signals from CryptoQuant's proprietary PnL Index chart, which now reflects a sell signal that has historically aligned with prior market tops.
What Happened: "We are likely past the bull cycle peak," Ju <a href="https://x.com/ki_young_ju/status/1901776141024989658">said</a>, suggesting Bitcoin may face a prolonged period of sideways or bearish movement over the next six to twelve months.
The chart, spanning over a decade, plots Bitcoin's price alongside cyclical buy and sell signals derived from on-chain profitability metrics. 
The latest signal indicates a similar pattern to those seen in 2013, 2017, and 2021, each of which preceded either steep corrections or extended consolidation phases.
Bitcoin currently trades around $81,550, holding above key psychological levels despite broader market caution. 
This resilience is echoed by Nexo Dispatch analyst Iliya Kalchev, who described the market as entering a crucial consolidation phase. 
"Bitcoin is at a critical juncture," Kalchev said. "Support is holding around $82,000, but deeper levels near $73,000 may come into play depending on market sentiment."
While recent inflows to U.S. spot Bitcoin ETFs suggest some institutional confidence—<a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44377037/bitcoin-meanders-around-82500-as-etfs-net-275-million-in-inflows">with $274 million in net inflows recorded on Monda</a>y—the broader sentiment remains mixed amid macroeconomic uncertainty.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44374846/presearch-bolsters-web3-transition-with-pre-token-beta-launch-on-base-layer-2">Presearch Bolsters Web3 Transition With PRE Token Beta Launch On Base Layer 2</a>
"The renewed ETF interest could be a positive driver, but this market could still go in many directions," Kalchev added.
CryptoQuant's cyclical analysis reinforces these concerns, showing that Bitcoin tends to experience cooling-off periods following major cyclical tops. 
The historical chart's orange sell indicators, including the latest signal for 2025, have often been followed by six to twelve months of weak or sideways performance before new buying opportunities emerge.
The wider market is also reflecting caution. 
Kalchev noted Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) is hovering near $1,890, while Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>) slipped to around $124 amid broader weakness in altcoins.
What&#8217;s Next: Amid these technical factors, the market's next moves could hinge on Wednesday's U.S. Federal Reserve rate decision, which may influence risk asset sentiment globally.
<a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44379524/what-will-happen-to-bitcoin-prices-if-donald-trump-and-vladimir-putin-agree-on-a-ceasefire-in-ukraine">Geopolitical uncertainties</a> and inflationary risks tied to U.S. tariffs have cast a shadow over investor confidence.
"This is a market in wait mode. Vigilance is key as institutional players weigh both the macro backdrop and on-chain signals,&#8221; Kalchev said.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44374550/bernstein-targets-310-for-coinbase-stock-cites-lifting-regulatory-dark-cloud">Bernstein Targets $310 For Coinbase Stock, Cites Lifting &#8216;Regulatory Dark Cloud&#8217;</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$ETH

$SOL

Bitcoin Is 'Past The Bull Cycle Peak,' Top Analyst Warns

The U.S. retail market had a bit of a rollercoaster start to 2025. February <a href="https://www.benzinga.com/economics/macro-economic-events/25/03/44355195/retail-sales-rebound-less-than-expected-in-february-online-healthcare-spending-show-strong-gains">retail sales</a> <a href="https://www.benzinga.com/economics/macro-economic-events/25/03/44355195/retail-sales-rebound-less-than-expected-in-february-online-healthcare-spending-show-strong-gains">edged up a modest 0.2%</a>, but that came after a steep downward revision for January, which now clocks in at a 1.2% decline. Economists were looking for a more robust bounce-back of about 0.6%, but consumer spending couldn&#8217;t quite match it.
For investors, this is a key question: what does this imply for <a href="https://www.benzinga.com/etfs">retail-oriented ETFs</a>? Because these ETFs follow the performance of retail stocks, they can take a hit from changes in consumer consumption. Let&#8217;s look at how recent retail data may affect these ETFs and what to expect next.
How Retail ETFs Are Reacting
Retail ETFs such as the SPDR S&amp;P Retail ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XRT#NYSE">XRT</a>) and VanEck Retail ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RTH#NASDAQ">RTH</a>) provide investors with broad exposure to the industry. When consumers are spending more, these ETFs perform well. But when sales are weak, the effect can be uneven based on what is behind the numbers. In the past month, XRT has dipped as much as 13.93% and RTH, 7.42%.
February&#8217;s softer-than-expected growth might cause some short-term volatility, but not every sector of retail is suffering. Online shopping and health-related retail strength might see some ETFs perform better than others.
Also Read: <a href="https://www.benzinga.com/personal-finance/25/03/44360075/retail-giant-target-which-relies-on-china-for-30-of-its-merchandise-warns-of-profit-hit-as-trumps-trade-war-bites">Retail Giant Target, Which Relies On China For 30% Of Its Merchandise, Warns Of Profit Hit As Trump&#8217;s Trade War Bites</a>
Here&#8217;s a closer examination:
XRT, an equal-weighted fund, might come under some pressure because it distributes investments among a broad spectrum of retailers, some of which are suffering.
RTH, which relies more heavily on the likes of Amazon and Walmart, might fare better with the continued e-commerce strength.
Vanguard Consumer Discretionary Index Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VCR#NYSE">VCR</a>), which is exposed to brick-and-mortar as well as online stores, may have mixed results based on how various retail categories perform.
Dissecting The Retail Sales Figures
Based on the most recent U.S. Census Bureau report, here&#8217;s how retail sales held up:
<ul>
<li>February sales increased 0.2%—a modest increase but not the recovery economists were looking for.</li>
<li>January sales were revised to a 1.2% decline, emphasizing a softer beginning to the year.</li>
<li>Year-over-year, retail sales increased 3.1%, decelerating from the prior 3.9%.</li>
</ul>
Not all categories fared poorly, however. Online stores experienced a 2.4% increase in sales, demonstrating ongoing demand for e-commerce.
Health and personal care stores reported a 1.7% increase.
Excluding auto sales and gasoline stations, retail sales actually increased 0.5%, higher than the expected 0.4%.
The control group measure, which removes more erratic sectors, increased 1%, a robust bounce back from January&#8217;s 1% fall.
A number of factors probably held down consumer spending. 
<ul>
<li>Inflation is continuing to nibble at purchasing power, so shoppers are being more careful. </li>
<li>Increased interest rates might be deterring major purchases.</li>
<li>January&#8217;s weakness might have lingered, as shoppers pulled back after the holidays. </li>
<li>Changing consumer spending, with greater emphasis on necessities over discretionary goods.</li>
</ul>
While the disappointing top-line number is concerning, there are some silver linings in sight. The fact that online sales were strong indicates that e-commerce retailers continue to draw shoppers. That&#8217;s a plus for ETFs that have heavy exposure to e-commerce stocks.
What&#8217;s Next For Retail ETFs?
While retail sales missed the mark, sector-specific strength—particularly in e-commerce—may cushion the blow for some ETFs. Investors will want to watch inflation, interest rates, and overall consumer sentiment in the months ahead.
For those who want to ride out possible volatility, diversification within the retail space may be the way to go. Although broad retail ETFs may face some stress, those funds that have greater exposure to well-performing sub-sectors such as e-retail and medical products could be in better shape in the near term.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44363430/covered-call-etfs-a-smart-income-play-in-volatile-markets">Covered Call ETFs: A Smart Income Play In Volatile Markets</a></li>
</ul>
Photo: Shutterstock

Sector ETFs

ETFs

Merrill Lynch Retail HOLDRS Trust due 12/31/41

Consumer Spending Stumbles: Time To Buy The Dip In Retail ETFs?

HYPR

Hyperfine shares are trading lower after the company reported worse-than-expected Q4 sales results.

HC Wainwright &amp; Co. analyst Ed Arce reiterates Pliant Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRX#NASDAQ">PLRX</a>) from Neutral to Neutral.

PLRX

HC Wainwright & Co. Reiterates Neutral on Pliant Therapeuticsto Neutral

Morgan Stanley analyst Tejas Savant maintains GRAIL (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRAL#NASDAQ">GRAL</a>) with a Equal-Weight and raises the price target from $16 to $20.

GRAL

Morgan Stanley Maintains Equal-Weight on GRAIL, Raises Price Target to $20

Press Releases

Genmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) Annual Meeting

Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis

Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2024

Genmab Publishes 2024 Annual Report

EPKINLY® (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare for Additional Indication as a Treatment for Relapsed or Refractory Follicular Lymphoma

Comments

Genmab

뉴스

파트너 / 기고자

벤징가 글로벌